Factor Report

Data as of market close on 9/27/2022.

Validea's factor report analyzes any stock using the major investing factors, including value, quality, momentum, and low volatility.
View User Guide    Video Tutorial

HERON THERAPEUTICS INC (HRTX)

View Guru Analysis
Latest Close: $4.02 Market Cap ($ mil): $413 Sector: Healthcare Industry: Major Drugs 52 Week High: $12.79 52 Week Low: $2.19 Relative Strength: 21 Twelve Minus One Return: -64.9% Standard Deviation: 66.8%
PE Ratio: N/A Price/Sales: 4.3 Price/Book: 5.3 Price/Cash Flow: N/A EV/EBITDA: N/A Yield: N/A Shareholder Yield: -12.09% F Score: 3 G Score: 2
Return on Equity: -328.5% Return on Assets: -70.1% Return on Tangible Capital: -161.9% Return on Invested Capital: N/A WACC: 5.9% Debt/Equity: 1.92 LT EPS Growth: N/A LT Sales Growth: 55.1% Beta: 1.10
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.

Factor Profile

HRTX's exposure to the major factors (100 is highest).

Comparable Stocks

Stocks with the closest factor profiles to HRTX.

(click ticker to access stock report and name to view guru analysis)

Ticker Ticker
CERS CDNA
OCUL BLUE
AMRS DOMO
Performance Disclaimer: Returns presented on Validea.com are model returns and do not represent actual trading. As a result, they do not incorporate any commissions or other trading costs or fees. Model portfolios with inception dates on or after 12/30/2005 include a combination of back tested and live model returns. The back-tested performance results shown are hypothetical and are not the result of real-time management of actual accounts. The back-testing of performance differs from actual account performance because the investment strategy may be adjusted at any time, for any reason and can continue to be changed until desired or better performance results are achieved. Back-tested returns are presented to provide general information regarding how the underlying strategy behind the portfolio performed in our historical testing. A back-tested strategy has the benefit of hindsight and the results do not reflect the impact that material economic or market factors may have had on advisor's decision-making if actual client assets were being managed using this approach. The model portfolios offered on Validea are concentrated and as a result they will exhibit high levels of volatility and their performance can be substantially impacted by the performance of individual positions.

Optimal portfolios presented on Validea.com represent the rebalancing period that has led to the best historical performance for each of our equity models. Each optimal portfolio was determined after the fact with performance information that was not available at portfolio inception. As a result, an investor could not have invested in the optimal portfolio since its inception. Optimal portfolios are presented to allow investors to quickly determine the portfolio size and rebalancing period that has performed best for each of our models in our historical testing.

Both the model portfolio and benchmark returns presented for all equity portfolios on Validea.com are not inclusive of dividends. Returns for our ETF portfolios and trend following system, and the benchmarks they are compared to, are inclusive of dividends. The S&P 500 is presented as a benchmark because it is the most widely followed benchmark of the overall US market and is most often used by investors for return comparison purposes. As with any investment strategy, there is potential for profit as well as the possibility of loss and investors may incur a loss despite a past history of gains. Past performance does not guarantee future results. Results will vary with economic and market conditions.